NASDAQ:LJPC - La Jolla Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$32.24 +0.47 (+1.48 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$32.24
Today's Range$31.75 - $32.5566
52-Week Range$22.68 - $41.36
Volume185,875 shs
Average Volume506,508 shs
Market Capitalization$831.19 million
P/E Ratio-5.96
Dividend YieldN/A
Beta1.42

About La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical logoLa Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. The company is developing LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264

Debt

Debt-to-Equity RatioN/A
Current Ratio10.09
Quick Ratio10.04

Price-To-Earnings

Trailing P/E Ratio-5.96
Forward P/E Ratio-4.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$620,000.00
Price / Sales1,359.80
Cash FlowN/A
Price / CashN/A
Book Value$5.76 per share
Price / Book5.60

Profitability

EPS (Most Recent Fiscal Year)($5.41)
Net Income$-114,800,000.00
Net MarginsN/A
Return on Equity-118.62%
Return on Assets-97.15%

Miscellaneous

Employees309
Outstanding Shares26,150,000

La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($2.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by $0.74. The biopharmaceutical company earned $0.81 million during the quarter. View La Jolla Pharmaceutical's Earnings History.

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for La Jolla Pharmaceutical.

What price target have analysts set for LJPC?

6 Wall Street analysts have issued 1 year target prices for La Jolla Pharmaceutical's stock. Their forecasts range from $20.00 to $100.00. On average, they expect La Jolla Pharmaceutical's stock price to reach $58.6667 in the next twelve months. View Analyst Ratings for La Jolla Pharmaceutical.

What are Wall Street analysts saying about La Jolla Pharmaceutical stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (5/17/2018)
  • 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) 660.6 Market Cap (M) $815 Public Market Float (M) 6.0 Shares Outstanding (M) 26.2 3 Interest (M) 7.32 Cash (M) $154.4 Total Debt (M) $0.0 Quarterly EPS may not sum to total due to rounding or change in share count." (5/11/2018)
  • 3. Chardan Capital analysts commented, "We see La Jolla Pharmaceutical as a remarkably de-risked rare disease story, and thus one deserving of higher conviction now, than the high conviction we had a year ago. With our 24 January 2017 research, we made La Jolla a Chardan Top Pick for 2017 based on (1) La Jolla’s approach being one of the more compelling and convincing rare disease strategies in biotech…[due to] focusing on naturally-occurring peptides with well-established biological functions" and (2) confidence the company will produce positive [pivotal Giapreza] ATHOS-3 phase III results" in 1Q17." (1/25/2018)

Who are some of La Jolla Pharmaceutical's key competitors?

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the folowing people:
  • Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 58)
  • Mr. Dennis M. Mulroy, CFO & Principal Accounting Officer (Age 63)
  • Ms. Jennifer A. Carver MBA, Chief Operating Officer (Age 64)
  • Dr. Lakhmir S. Chawla M.D., Chief Medical Officer (Age 47)
  • Mr. James M. Rolke, Chief Scientific Officer (Age 49)

Has La Jolla Pharmaceutical been receiving favorable news coverage?

Press coverage about LJPC stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. La Jolla Pharmaceutical earned a coverage optimism score of 0.21 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (15.83%), TANG CAPITAL PARTNERS LP (16.50%), BLACKROCK INC. (4.60%), BlackRock Inc. (4.46%), Scopia Capital Management LP (2.21%) and Candriam Luxembourg S.C.A. (1.33%). Company insiders that own La Jolla Pharmaceutical stock include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.

Which major investors are selling La Jolla Pharmaceutical stock?

LJPC stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, GSA Capital Partners LLP, BlackRock Inc. and Allianz Asset Management GmbH. View Insider Buying and Selling for La Jolla Pharmaceutical.

Which major investors are buying La Jolla Pharmaceutical stock?

LJPC stock was acquired by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Scopia Capital Management LP, Artal Group S.A., Rock Springs Capital Management LP, UBS Group AG, Candriam Luxembourg S.C.A., Asymmetry Capital Management L.P. and Cowen Inc.. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $32.24.

How big of a company is La Jolla Pharmaceutical?

La Jolla Pharmaceutical has a market capitalization of $831.19 million and generates $620,000.00 in revenue each year. The biopharmaceutical company earns $-114,800,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis. La Jolla Pharmaceutical employs 309 workers across the globe.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]


MarketBeat Community Rating for La Jolla Pharmaceutical (LJPC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

La Jolla Pharmaceutical (NASDAQ:LJPC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for La Jolla Pharmaceutical in the last 12 months. Their average twelve-month price target is $58.6667, suggesting that the stock has a possible upside of 81.97%. The high price target for LJPC is $100.00 and the low price target for LJPC is $20.00. There are currently 2 sell ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.432.433.00
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $58.6667$58.6667$60.00$54.60
Price Target Upside: 81.97% upside105.70% upside62.91% upside71.00% upside

La Jolla Pharmaceutical (NASDAQ:LJPC) Consensus Price Target History

Price Target History for La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical (NASDAQ:LJPC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018HC WainwrightReiterated RatingBuy$72.00 ➝ $83.00HighView Rating Details
2/12/2018Jefferies GroupDowngradeBuy ➝ Underperform$40.00 ➝ $29.00HighView Rating Details
1/25/2018Chardan CapitalBoost Price TargetNeutral ➝ Buy$90.00 ➝ $100.00HighView Rating Details
12/28/2017SunTrust BanksSet Price TargetBuy$57.00 ➝ $65.00LowView Rating Details
12/22/2017CowenReiterated RatingBuy$55.00MediumView Rating Details
12/22/2017JPMorgan Chase & Co.Reiterated RatingSellHighView Rating Details
4/30/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/24/2016Lake Street CapitalInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

La Jolla Pharmaceutical (NASDAQ:LJPC) Earnings History and Estimates Chart

Earnings by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical (NASDAQ:LJPC) Earnings Estimates

2018 EPS Consensus Estimate: ($4.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.20)($1.20)($1.20)
Q2 20181($1.23)($1.23)($1.23)
Q3 20181($0.96)($0.96)($0.96)
Q4 20181($0.94)($0.94)($0.94)

La Jolla Pharmaceutical (NASDAQ LJPC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2018        
5/10/2018Q1 2018($1.4820)($2.2220)$0.81 millionViewN/AView Earnings Details
2/22/2018Q4 2017($1.25)($1.74)ViewN/AView Earnings Details
10/26/2017Q3 2017($1.2420)($1.19)ViewN/AView Earnings Details
7/27/2017Q2 2017($1.1250)($1.21)$0.03 millionViewN/AView Earnings Details
4/27/2017Q1 2017($1.3420)($1.26)$0.17 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.20)($1.44)$0.16 million$0.09 millionViewN/AView Earnings Details
11/3/2016Q3($0.97)($1.23)$0.26 million$0.04 millionViewN/AView Earnings Details
8/8/2016Q2($0.99)($0.90)$0.25 million$0.25 millionViewN/AView Earnings Details
5/6/2016Q416($0.74)($0.96)$0.43 million$0.23 millionViewN/AView Earnings Details
2/25/2016Q4($0.7170)($0.69)$0.41 millionViewN/AView Earnings Details
11/6/2015Q315($0.69)($0.70)$0.65 millionViewN/AView Earnings Details
8/7/2015Q215($0.61)($0.70)ViewN/AView Earnings Details
4/29/2015Q1 2015($0.50)($0.59)ViewN/AView Earnings Details
3/16/2015Q414($0.37)($0.45)ViewN/AView Earnings Details
11/12/2014Q314($0.42)($0.37)ViewN/AView Earnings Details
8/14/2014Q214($0.69)($0.63)ViewN/AView Earnings Details
4/30/2014Q1 2014($0.91)($0.93)ViewN/AView Earnings Details
3/31/2014($0.24)($0.07)ViewN/AView Earnings Details
11/8/2013Q3 2013($5.50)ViewN/AView Earnings Details
7/19/2013Q2 2013($7.00)ViewN/AView Earnings Details
5/13/2013Q1 2013($12.50)ViewN/AView Earnings Details
4/1/2013Q4 2012($14.00)ViewN/AView Earnings Details
11/9/2012Q3 2012($450.00)ViewN/AView Earnings Details
8/10/2012Q2 2012($33.50)ViewN/AView Earnings Details
3/30/2012Q4 2011($593.80)ViewN/AView Earnings Details
8/17/2009Q2 2009($15,500.00)ViewN/AView Earnings Details
10/31/2008Q3 2008($150,000.00)($155,000.00)ViewN/AView Earnings Details
8/4/2008Q2 2008($175,000.00)($155,000.00)ViewN/AView Earnings Details
5/1/2008Q1 2008($180,000.00)($172,000.00)ViewN/AView Earnings Details
2/28/2008Q4 2007($180,000.00)($182,000.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

La Jolla Pharmaceutical (NASDAQ:LJPC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

La Jolla Pharmaceutical (NASDAQ LJPC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.47%
Insider Trading History for La Jolla Pharmaceutical (NASDAQ:LJPC)
Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical (NASDAQ LJPC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Kevin C TangDirectorBuy508,474$29.50$14,999,983.00View SEC Filing  
3/15/2018Perceptive Advisors LlcMajor ShareholderBuy700,000$29.50$20,650,000.00View SEC Filing  
3/2/2018Kevin C TangDirectorBuy10,000$30.44$304,400.00View SEC Filing  
2/27/2018Kevin C TangDirectorBuy150,000$31.82$4,773,000.00View SEC Filing  
2/23/2018Jennifer CarverCOOBuy1,000$32.48$32,480.005,500View SEC Filing  
2/14/2018Life Sciences Maste PerceptiveMajor ShareholderBuy175,000$32.72$5,726,000.00View SEC Filing  
12/29/2017Laura L DouglassDirectorSell10,000$32.32$323,200.00View SEC Filing  
12/29/2017Laura L DouglassDirectorSell10,000$32.32$323,200.006,000View SEC Filing  
12/27/2017Jennifer CarverCOOBuy1,000$33.22$33,220.004,500View SEC Filing  
12/27/2017Jennifer CarverCOOBuy1,000$33.22$33,220.004,500View SEC Filing  
3/23/2017Kevin C TangDirectorBuy149,254$33.50$5,000,009.00View SEC Filing  
3/3/2017Dennis MulroyCFOBuy500$33.95$16,975.00500View SEC Filing  
3/3/2017George F TidmarshCEOBuy3,000$34.17$102,510.001,353,086View SEC Filing  
3/3/2017Lakhmir S ChawlaInsiderBuy1,600$34.80$55,680.001,085View SEC Filing  
9/13/2016Kevin C TangDirectorBuy139,035$19.82$2,755,673.70View SEC Filing  
3/4/2016Kevin C TangDirectorBuy20,000$19.85$397,000.00View SEC Filing  
3/1/2016George F TidmarshCEOBuy2,000$16.57$33,140.001,424,086View SEC Filing  
9/28/2015Lakhmir S ChawlaInsiderBuy485$27.75$13,458.75485View SEC Filing  
9/10/2015Kevin C TangDirectorBuy80,000$38.00$3,040,000.00View SEC Filing  
8/21/2015Kevin C TangDirectorBuy170,000$27.11$4,608,700.00View SEC Filing  
6/26/2015Kevin C TangDirectorBuy110,000$23.58$2,593,800.00View SEC Filing  
6/24/2015Kevin C TangDirectorBuy220,000$22.23$4,890,600.00View SEC Filing  
6/23/2015Kevin C TangDirectorBuy53,836$22.27$1,198,927.72View SEC Filing  
6/22/2015Kevin C TangDirectorBuy77,850$21.41$1,666,768.50View SEC Filing  
5/13/2015Kevin C TangDirectorBuy190,583$18.24$3,476,233.92View SEC Filing  
5/12/2015George F TidmarshCEOBuy4,000$18.37$73,480.00View SEC Filing  
12/15/2014Kevin C TangDirectorBuy232,343$12.84$2,983,284.12View SEC Filing  
12/11/2014George F TidmarshCEOBuy4,000$11.38$45,520.00View SEC Filing  
9/26/2014George F TidmarshCEOBuy2,000$9.35$18,700.00View SEC Filing  
9/26/2014Kevin C TangDirectorBuy169,555$9.14$1,549,732.70View SEC Filing  
9/25/2014Kevin C TangDirectorBuy30,500$9.17$279,685.00View SEC Filing  
9/24/2014Kevin C TangDirectorBuy95,000$9.10$864,500.00View SEC Filing  
9/18/2014George F TidmarshCEOBuy5,000$9.18$45,900.00View SEC Filing  
7/23/2014George F TidmarshCEOBuy19,000$10.50$199,500.00View SEC Filing  
5/21/2014George TidmarshCEOBuy12,000$7.37$88,440.001,391,086View SEC Filing  
4/14/2014George TidmarshCEOBuy8,000$9.53$76,240.001,391,086View SEC Filing  
2/7/2014George F TidmarshCEOBuy3,000$7.25$21,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

La Jolla Pharmaceutical (NASDAQ LJPC) News Headlines

Source:
DateHeadline
Recent Analysis Shows Engility, La Jolla Pharmaceutical, Freshpet, At Home Group, Dennys, and SP Plus Market ...Recent Analysis Shows Engility, La Jolla Pharmaceutical, Freshpet, At Home Group, Denny's, and SP Plus Market ...
www.globenewswire.com - May 21 at 8:38 AM
ValuEngine Lowers La Jolla Pharmaceutical (LJPC) to HoldValuEngine Lowers La Jolla Pharmaceutical (LJPC) to Hold
www.americanbankingnews.com - May 18 at 11:20 PM
La Jolla Pharmaceutical (LJPC) Expected to Post Quarterly Sales of $2.03 MillionLa Jolla Pharmaceutical (LJPC) Expected to Post Quarterly Sales of $2.03 Million
www.americanbankingnews.com - May 18 at 5:00 AM
La Jolla Pharmaceutical (LJPC) Cut to Sell at Zacks Investment ResearchLa Jolla Pharmaceutical (LJPC) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 17 at 4:59 PM
La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology AssociationLa Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association
feeds.benzinga.com - May 17 at 1:57 PM
Global Kidney fibrosis treatment Market Growth Opportunities: La Jolla Pharmaceutical CompanyGlobal Kidney fibrosis treatment Market Growth Opportunities: La Jolla Pharmaceutical Company
www.marketwatch.com - May 16 at 8:54 AM
-$1.34 Earnings Per Share Expected for La Jolla Pharmaceutical (LJPC) This Quarter-$1.34 Earnings Per Share Expected for La Jolla Pharmaceutical (LJPC) This Quarter
www.americanbankingnews.com - May 16 at 5:21 AM
La Jollas Financial Deal Is A Major Boost To Get The Ball RollingLa Jolla's Financial Deal Is A Major Boost To Get The Ball Rolling
seekingalpha.com - May 14 at 9:05 AM
La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty ...La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty ...
globenewswire.com - May 12 at 5:17 PM
BRIEF-La Jolla Pharmaceutical Co Announces $125 Mln Royalty Financing Agreement With Healthcare Royalty PartnersBRIEF-La Jolla Pharmaceutical Co Announces $125 Mln Royalty Financing Agreement With Healthcare Royalty Partners
www.reuters.com - May 12 at 5:17 PM
What Should We Expect From La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) Earnings In The Next Couple Of Years?What Should We Expect From La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) Earnings In The Next Couple Of Years?
finance.yahoo.com - May 12 at 9:05 AM
La Jolla Pharmaceutical (LJPC) Receives Buy Rating from HC WainwrightLa Jolla Pharmaceutical (LJPC) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - May 11 at 5:49 PM
La Jolla Pharmaceutical (LJPC) Issues  Earnings Results, Misses Expectations By $0.74 EPSLa Jolla Pharmaceutical (LJPC) Issues Earnings Results, Misses Expectations By $0.74 EPS
www.americanbankingnews.com - May 11 at 2:19 PM
La Jolla Pharmaceutical (LJPC) Enters $125 Million Royalty Financing Agreement with HealthCare Royalty PartnersLa Jolla Pharmaceutical (LJPC) Enters $125 Million Royalty Financing Agreement with HealthCare Royalty Partners
www.streetinsider.com - May 11 at 9:10 AM
La Jolla Pharmaceutical misses by $0.74La Jolla Pharmaceutical misses by $0.74
seekingalpha.com - May 11 at 9:10 AM
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate ProgressLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
finance.yahoo.com - May 10 at 5:26 PM
La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty PartnersLa Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners
finance.yahoo.com - May 10 at 5:26 PM
La Jolla Pharmaceutical (LJPC) Receives Average Recommendation of "Hold" from BrokeragesLa Jolla Pharmaceutical (LJPC) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 10 at 4:59 PM
La Jolla Pharmaceutical (LJPC) versus Gilead Sciences (GILD) Head-To-Head ReviewLa Jolla Pharmaceutical (LJPC) versus Gilead Sciences (GILD) Head-To-Head Review
www.americanbankingnews.com - May 8 at 9:26 PM
La Jolla Pharmaceutical (LJPC) Upgraded by ValuEngine to "Buy"La Jolla Pharmaceutical (LJPC) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - May 3 at 12:39 AM
CalciMedica Names Two Senior Executives to its Board of DirectorsCalciMedica Names Two Senior Executives to its Board of Directors
finance.yahoo.com - May 2 at 8:44 AM
La Jolla Pharmaceutical (LJPC) Stock Rating Lowered by ValuEngineLa Jolla Pharmaceutical (LJPC) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 20 at 12:24 AM
Zacks Investment Research Lowers La Jolla Pharmaceutical (LJPC) to HoldZacks Investment Research Lowers La Jolla Pharmaceutical (LJPC) to Hold
www.americanbankingnews.com - April 17 at 9:48 PM
La Jolla Pharmaceutical (LJPC) Stock Rating Upgraded by Zacks Investment ResearchLa Jolla Pharmaceutical (LJPC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:17 AM
La Jolla Pharmaceutical (LJPC) Rating Reiterated by Jefferies GroupLa Jolla Pharmaceutical (LJPC) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 16 at 12:37 PM
La Jolla Pharmaceutical (LJPC) Given Average Recommendation of "Hold" by BrokeragesLa Jolla Pharmaceutical (LJPC) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 4:07 PM
La Jolla Pharmaceutical (LJPC) Downgraded by BidaskClub to SellLa Jolla Pharmaceutical (LJPC) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - April 13 at 4:23 PM
La Jolla Pharmaceutical (LJPC) Raised to Hold at BidaskClubLa Jolla Pharmaceutical (LJPC) Raised to Hold at BidaskClub
www.americanbankingnews.com - April 11 at 9:31 PM
La Jolla Pharmaceutical (LJPC) Upgraded at ValuEngineLa Jolla Pharmaceutical (LJPC) Upgraded at ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM
La Jolla Pharmaceutical (LJPC) Downgraded by Zacks Investment ResearchLa Jolla Pharmaceutical (LJPC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 7:17 PM
La Jolla Pharmaceutical (LJPC) Upgraded to Hold at Zacks Investment ResearchLa Jolla Pharmaceutical (LJPC) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 10:54 AM
La Jolla Pharmaceutical Sees Unusually Large Options Volume (LJPC)La Jolla Pharmaceutical Sees Unusually Large Options Volume (LJPC)
www.americanbankingnews.com - April 4 at 8:07 AM
La Jolla Pharmaceutical (LJPC) Rating Lowered to Strong Sell at ValuEngineLa Jolla Pharmaceutical (LJPC) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 3 at 12:44 PM
La Jolla Pharmaceutical (LJPC) Raised to "Buy" at Zacks Investment ResearchLa Jolla Pharmaceutical (LJPC) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 2 at 6:26 PM
La Jolla Pharmaceutical (LJPC) Downgraded by BidaskClubLa Jolla Pharmaceutical (LJPC) Downgraded by BidaskClub
www.americanbankingnews.com - March 29 at 4:10 PM
La Jolla Pharmaceutical (LJPC) Upgraded at BidaskClubLa Jolla Pharmaceutical (LJPC) Upgraded at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
La Jolla Pharmaceutical (LJPC) Major Shareholder Buys $20,650,000.00 in StockLa Jolla Pharmaceutical (LJPC) Major Shareholder Buys $20,650,000.00 in Stock
www.americanbankingnews.com - March 26 at 10:28 PM
BidaskClub Lowers La Jolla Pharmaceutical (LJPC) to SellBidaskClub Lowers La Jolla Pharmaceutical (LJPC) to Sell
www.americanbankingnews.com - March 24 at 8:23 PM
BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United StatesBRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States
www.reuters.com - March 23 at 8:47 AM
La Jolla Pharma launches Giapreza in U.S.La Jolla Pharma launches Giapreza in U.S.
seekingalpha.com - March 23 at 8:47 AM
Investors Purchase High Volume of Put Options on La Jolla Pharmaceutical (LJPC)Investors Purchase High Volume of Put Options on La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - March 23 at 7:04 AM
La Jolla Pharmaceutical (LJPC) Price Target Cut to $83.00 by Analysts at HC WainwrightLa Jolla Pharmaceutical (LJPC) Price Target Cut to $83.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 22 at 8:12 PM
La Jolla Pharmaceutical (LJPC) Announces Launch of GIAPREZA in the United States - StreetInsider.comLa Jolla Pharmaceutical (LJPC) Announces Launch of GIAPREZA in the United States - StreetInsider.com
www.streetinsider.com - March 22 at 5:14 PM
La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United StatesLa Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States
finance.yahoo.com - March 22 at 5:14 PM
La Jolla Pharmaceutical (LJPC) Receives Average Recommendation of "Hold" from AnalystsLa Jolla Pharmaceutical (LJPC) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 3:49 PM
Kevin C. Tang Buys 508,474 Shares of La Jolla Pharmaceutical (LJPC) StockKevin C. Tang Buys 508,474 Shares of La Jolla Pharmaceutical (LJPC) Stock
www.americanbankingnews.com - March 19 at 10:10 PM
La Jolla Pharma prices stock offering at $29.50; shares up 1% premarketLa Jolla Pharma prices stock offering at $29.50; shares up 1% premarket
seekingalpha.com - March 15 at 8:41 AM
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common StockLa Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 15 at 8:41 AM
La Jolla Pharmaceutical (LJPC) to Offer $100M in Common Stock - StreetInsider.comLa Jolla Pharmaceutical (LJPC) to Offer $100M in Common Stock - StreetInsider.com
www.streetinsider.com - March 14 at 6:35 PM
La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common StockLa Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock
finance.yahoo.com - March 14 at 6:35 PM

SEC Filings

La Jolla Pharmaceutical (NASDAQ:LJPC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

La Jolla Pharmaceutical (NASDAQ:LJPC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

La Jolla Pharmaceutical (NASDAQ LJPC) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.